ZIOPHARM Oncology Inc (NASDAQ: ZIOP) stock suffered a major decline of -12.0% on 5/28/20. The shares closed at $3.07. Moreover, trading volume in this decline was unusually high at 152% of normal. The stock has been weak relative to the market over the last nine months but has risen 11.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, ZIOP is expected to be a major Value Eraser.
ZIOPHARM Oncology has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. ZIOPHARM Oncology has a poor Power Rating of 24 and a very low Appreciation Score of 3, producing the Lowest Value Trend Rating.
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.